Investing in Sage Therapeutics Inc. (SAGE) Is Getting More Attractive

0
11

Sage Therapeutics Inc.’s recent filing unveils that its Director Golumbeski George acquired Company’s shares for reported $0.25 million on May 05. In the deal valued at $31.45 per share,8,000 shares were bought. As a result of this transaction, Golumbeski George now holds 8,000 shares worth roughly $ 0.28 million.


3 Tiny Stocks Primed to Explode The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.

We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.

Click here for full details and to join for free.

Sponsored


Loop Capital initiated its Sage Therapeutics Inc. [SAGE] rating to a Hold in a research note published on Friday, November 01, 2022; the price target was $41. PT values the company’s stock at a premium of 15.17 to its Friday closing price. A number of analysts have revised their coverage, including Berenberg’s analysts, who began to cover the stock in late March with a ‘”a Hold”‘ rating. Guggenheim also remained covering SAGE and has increased its forecast on November 02, 2021 with a “Buy” recommendation from previously “Neutral” rating.

Price Performance Review of SAGE

On Friday, Sage Therapeutics Inc. [NASDAQ:SAGE] saw its stock fall -5.05% to $34.78. On the same session, the stock had its day’s lowest price of $34.015, but rose to a high of $36.75. Over the last five days, the stock has lost -9.00%. Sage Therapeutics Inc. shares have fallen nearly -18.24% since the year began. Nevertheless, the stocks have fallen -25.48% over the past one year. While a 52-week high of $47.75 was reached on 02/09/22, a 52-week low of $27.36 was recorded on 05/09/22. SMA at 50 days reached $38.91, while 200 days put it at $36.46. A total of 0.56 million shares were traded, compared to the trading of 0.31 million shares in the previous session.

Levels Of Support And Resistance For SAGE Stock

The 24-hour chart illustrates a support level at 33.61, which if violated will result in even more drops to 32.45. On the upside, there is a resistance level at 36.35. A further resistance level may holdings at 37.92. The Relative Strength Index (RSI) on the 14-day chart is 35.26, which indicates neutral technical sentiment, while the Moving Average Convergence Divergence (MACD) stands at -0.76, which suggests price will go down in the next trading period. Percent R suggests that price movement has been bearish at 85.67%. Stochastics %K at 30.48% indicates the stock is a holding.

How much short interest is there in Sage Therapeutics Inc.?

A steep rise in short interest was recorded in Sage Therapeutics Inc. stocks on Jul 14, 2022, growing by 0.44 million shares to a total of 3.56 million shares. Yahoo Finance data shows the prior-month short interest on Jun 14, 2022 was 3.12 million shares. There was a rise of 12.36%, which implies that there is a positive sentiment for the stock. In spite of short shares comprising just 8.00% of the overall stock float, the days-to-cover ratio (short ratio) rose to 3.34.

Sage Therapeutics Inc. [SAGE] – Who Are The Largest Shareholders?

In filings from Fidelity Management & Research Co, it is revealed that the company now owns 5,977,078 shares, or roughly 10.06% of the outstanding SAGE shares. In other words, the investor’s shares have risen by 345,566 from its previous 13-F filing of 5631512.0. Additionally, Wellington Management Co. LLP decreased -32.10% of its stake after which the total value it holdings stand at $185,995,237, while The Vanguard Group, Inc. added 2.11% of its stake to hold $182.36 million in the firm. Over the last quarter, BlackRock Fund Advisors purchased 1,368,312 shares of Sage Therapeutics Inc., while Bellevue Asset Management AG bought -79,226 shares. At present, SSgA Funds Management, Inc. is holding 2,934,064 shares valued at $114.9 million. T. Rowe Price Associates, Inc. owned 2,077,534 shares of the company at the time of its most recent 13F filing, worth $81.36 million.

LEAVE A REPLY

Please enter your comment!
Please enter your name here